SECURITIES AND EXCHANGE COMMISSION
WASHINGTON DC 20549
-------------
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of earliest event reported) August 24, 1999
---------------
LEUKOSITE, INC.
--------------------------------------------------
(Exact Name of Registrant as Specified in Charter)
DELAWARE 0-22769 04-3173859
- ------------------------------------------------------------------------------
(State or Other Jurisdiction (Commission (IRS Employer
of Incorporation File Number Identification No.)
215 First Street, Cambridge, MA 02142
---------------------------------------------------
(Address of Principal Executive Offices) (Zip Code)
Registrant's telephone number, including area code (617) 621-9350
-2-
ITEM 5. OTHER EVENTS.
On August 24, 1999, LeukoSite announced that L&I Partners, L.P., a joint venture
which LeukoSite has with ILEX Oncology, Inc., entered into an agreement with
Schering AG for the marketing and distribution of CAMPATH(TM) in the United
States, Europe and the rest of the world except for Japan and East Asia (where
LeukoSite and ILEX have retained rights). The Agreement is attached hereto as
Exhibit 99.1 and incorporated herein by reference. The foregoing description is
qualified by reference to such exhibit.
ITEM 7. FINANCIAL STATEMENTS, PRO FORMA FINANCIAL INFORMATION AND EXHIBITS.
(C) EXHIBITS.
*99.1 Distribution and Development Agreement between L&I Partners, L.P. and
Schering AG, dated August 24, 1999
* Confidential treatment requested: material has been omitted and filed
separately with the Commission.
-3-
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
LEUKOSITE, INC.
By: /s/ Augustine Lawlor
----------------------------------------------
Augustine Lawlor,
Chief Operating and Financial Officer and
Senior Vice President, Corporate
Development
Dated: September 3, 1999